CA3219993A1 - Medium molecular weight heparin for use in the treatment of endotheliopathy - Google Patents

Medium molecular weight heparin for use in the treatment of endotheliopathy Download PDF

Info

Publication number
CA3219993A1
CA3219993A1 CA3219993A CA3219993A CA3219993A1 CA 3219993 A1 CA3219993 A1 CA 3219993A1 CA 3219993 A CA3219993 A CA 3219993A CA 3219993 A CA3219993 A CA 3219993A CA 3219993 A1 CA3219993 A1 CA 3219993A1
Authority
CA
Canada
Prior art keywords
molecular weight
medium molecular
weight heparin
vwf
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219993A
Other languages
English (en)
French (fr)
Inventor
Pervinder Singh Bhogal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycos Biomedical Ltd
Original Assignee
Glycos Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycos Biomedical Ltd filed Critical Glycos Biomedical Ltd
Publication of CA3219993A1 publication Critical patent/CA3219993A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3219993A 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy Pending CA3219993A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2106972.9 2021-05-14
GBGB2106972.9A GB202106972D0 (en) 2021-05-14 2021-05-14 Medium molecular weight heparin
PCT/EP2022/063222 WO2022238587A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy

Publications (1)

Publication Number Publication Date
CA3219993A1 true CA3219993A1 (en) 2022-11-17

Family

ID=76550734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219993A Pending CA3219993A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy

Country Status (8)

Country Link
US (1) US20240245718A1 (https=)
EP (1) EP4337225A1 (https=)
JP (1) JP2024517355A (https=)
CN (1) CN117915923A (https=)
AU (1) AU2022273186A1 (https=)
CA (1) CA3219993A1 (https=)
GB (1) GB202106972D0 (https=)
WO (1) WO2022238587A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106117A1 (en) * 2023-11-17 2025-05-22 Glycos Biomedical Ltd. Medium molecular weight heparin
WO2025245445A1 (en) * 2024-05-23 2025-11-27 Glycos Biomedical Ltd Functionalised medium molecular weight heparin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
EP3348270A1 (en) * 2017-01-11 2018-07-18 Fytagoras B.V. Medium molecular weight heparin
JP2021155334A (ja) * 2018-05-01 2021-10-07 学校法人近畿大学 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物
WO2022016098A1 (en) * 2020-07-17 2022-01-20 Xostem Ip, Inc. Compositions and methods for treatment of inflammatory and thromboinflammatory disorders using modified exosomes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106117A1 (en) * 2023-11-17 2025-05-22 Glycos Biomedical Ltd. Medium molecular weight heparin
WO2025245445A1 (en) * 2024-05-23 2025-11-27 Glycos Biomedical Ltd Functionalised medium molecular weight heparin

Also Published As

Publication number Publication date
GB202106972D0 (en) 2021-06-30
EP4337225A1 (en) 2024-03-20
US20240245718A1 (en) 2024-07-25
WO2022238587A1 (en) 2022-11-17
JP2024517355A (ja) 2024-04-19
CN117915923A (zh) 2024-04-19
AU2022273186A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
Best et al. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
Lutz Platelets in advanced chronic kidney disease: two sides of the coin
US20240245718A1 (en) Medium molecular weight heparin for use in the treatment of endotheliopathy
Liumbruno et al. Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period
Nilsson et al. The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies
Lowe Pathophysiology of critical leg ischaemia
Cohen Arazi et al. Anti-inflammatory effects of anti-platelet treatment in atherosclerosis
Jankowska-Sanetra et al. Incidence and course of acute coronary syndrome cases after the first wave of the COVID-19 pandemic
WO2024105271A1 (en) Preparation of medium molecular weight heparin
Nespola et al. Treatment-resistant acute upper limb ischemia in a patient with systemic lupus erythematous and concomitant SARS-CoV-2 infection: a case report
Vallely et al. Endothelial activation after coronary artery bypass surgery: comparison between on-pump and off-pump techniques
WO2025106117A1 (en) Medium molecular weight heparin
EP4619446A1 (en) Preparation of medium molecular weight heparin
HK40109661A (zh) 用於治疗内皮病的中分子量肝素
Armstrong et al. Pharmacology of hemostasis and thrombosis
Chivasso et al. Effectiveness and safety of Aprotinin use in thoracic aortic surgery
Kon et al. Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition
WO2025245445A1 (en) Functionalised medium molecular weight heparin
Ngu et al. Use of anticoagulants in COVID-19: a review
Rice et al. Argatroban therapy in heparin-induced thrombocytopenia
Oldgren et al. Xa inhibition and coagulation activity—the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals
Goubran et al. Coagulation and Anticoagulants
Permana et al. The Efficacy of Albumin Channa Striata Extract Administration in Stabilizing PAI-1 and Platelet Levels in Septic Patients: A Randomized Control Trial Study. Open Access Maced J Med Sci. 2022 Oct 28; 10 (B): 2313-2318
Stefano Barco et al. Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
Machaj et al. Upper extremity critical ischaemia in the course of sticky platelet syndrome

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250512

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260422